L.BissonJ.GrahamJ.PauliG
E66.3 for overweight) An ICD-10 code for the qualifying tier condition, where applicable The prescribing clinician's National Provider Identifier (NPI) and a statement that they are not on the CMS Preclusion List Documentation that the medication will be used alongside structured nutrition and physical activity Date of last clinical visit with the prescribing provider The specific medication being requested (Wegovy, Zepbound, or Foundayo) with dose and quantity Some Part D plans add requirements such as documented prior lifestyle intervention attempts, weight history over the past 24 months, or signed patient acknowledgment of the long-term nature of treatment
However, these protocols have yet to be evaluated in published literature
Lofton explains, Because GLP-1 agonists are gut hormones, the most common side effects are gastrointestinal. She adds, These can include nausea, constipation, diarrhea, reflux symptoms, and sometimes abdominal pain or even vomiting. She cautions that if anyone taking these medications has abdominal pain or vomiting, they should discuss it with their prescriber
This detoxification process is largely supported by glutathione
